MARKET

NURO

NURO

Neurometrix Inc
NASDAQ
3.510
-0.010
-0.28%
After Hours: 3.540 +0.03 +0.85% 16:00 04/16 EDT
OPEN
3.530
PREV CLOSE
3.520
HIGH
3.556
LOW
3.510
VOLUME
5.88K
TURNOVER
0
52 WEEK HIGH
12.04
52 WEEK LOW
2.700
MARKET CAP
6.97M
P/E (TTM)
-0.5601
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NURO last week (0408-0412)?
Weekly Report · 1d ago
Weekly Report: what happened at NURO last week (0401-0405)?
Weekly Report · 04/08 11:28
Weekly Report: what happened at NURO last week (0325-0329)?
Weekly Report · 04/01 11:25
Weekly Report: what happened at NURO last week (0318-0322)?
Weekly Report · 03/25 11:28
Weekly Report: what happened at NURO last week (0311-0315)?
Weekly Report · 03/18 11:26
NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia
Over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. The device is a transcutaneous electrical nerve stimulation device indicated to reduce the symptoms of fibromyalgia in adults with high pain sensitivity. NeuroMetrix says the company is pleased with the positive response to the product.
Benzinga · 03/13 13:08
Weekly Report: what happened at NURO last week (0304-0308)?
Weekly Report · 03/11 11:23
Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"
Ephraim Fields of Echo Lake Capital wrote a letter to the Board of Directors of Neurometrix, Inc. He believes the company should immediately liquidate because its stock price is trading significantly below its net cash per share. Notes tremendous destruction of shareholder value under company's leadership. Sees no reason for company to remain public.
Benzinga · 03/04 13:08
More
About NURO
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Webull offers Neurometrix Inc stock information, including NASDAQ: NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.